TP53 and Alzheimer disease: Thus, the observed reduction in p53 levels, as well as the diminished acetylation of p53, and the decreased Bax to Bcl-2 ratio following treatment with RSSW, highlight the potential of RSSW in mitigating neuronal apoptosis by modulating the SIRT1/p53 signaling pathway, thereby exhibiting promising anti-AD effects.